Merck Sharp + Dohme Corp.

Merck + Co., Inc.

University of California

Mitokinin, Inc.

Other

Certego Therapeutics Inc.

Robert J DeVita

Sander G Mills

Jinlong Jiang

Ping Liu

Jonathan R Young

Linus S Lin

Anthony K Ogawa

Peter Lin

Marc D Chioda

Jaime Lynn Bunda

Matthew J Wyvratt

Ravi P Nargund

Kevan M Shokat

Dong-Ming Shen

Hong Shen

Peter J Sinclair

Zhicai Wu

Richard Thomas Beresis

Richard J Bochis

William R Schoen

Harry R Chobanian

Yan Guo

Yuguang Wang

Ping Lan

Changhe Qi

Alejandro Crespo

John Qiang Tan

Zhongxiang Sun

Rudrajit Mal

Ellen K Vande Bunte

Min Shu

Nicholas T Hertz

Kun Liu

Jianming Bao

Feroze Ujjainwalla

Gregori J Morriello

Lehua Chang

Terence G Hamill

Andrew Kassick

Greg J Morriello

Kristin K Baldwin

Wenping Li

Pavel Osten

Sanjeev Kumar

Richard A Tschirret-Guth

Danny Chaung

MyLe Hoang

Andreas W Sailer

Samuel Desjardins

Jon Loglisci

Jeffrey Albert

Ring deuterated gaboxadol is provided. The ring deuterated gaboxadol is useful in the treatment of psychiatric disorders and is more effective than non-deuterated gaboxadol in such treatments. Deuterated gaboxadol is useful in combinations with other compounds to provide additive and synergistic effects for patient therapies. In a specific embodiment, the deuterated gaboxadol is d6-gaboxadol.

Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Disclosed herein inter alia are compositions and methods useful in the treatment neurodegenerative diseases and cardiomyopathy, and for modulating the activity of PINK1.

Compositions and methods for treating neurodegenerative diseases and cardiomyopathy

A handheld circular sawing device for severing armored cable includes a housing. A first plate is coupled to and extends coplanarly with a first side of the housing. A second plate is positioned substantially perpendicular to the first plate along a lower edge of the first plate. The second plate is hingedly coupled by a first end to the first plate proximate to a rear of the housing. A second end of the second plate is positioned proximate to a front of the housing to define a channel. A power module and a motor are coupled to the housing. The motor is operationally coupled to the power module. A blade that is coupled to a shaft of the motor protrudes into the channel. The motor is positioned to rotate the blade coincident with the shaft to longitudinally cut a section of a tubular substrate that is positioned in the channel.

Handheld circular sawing device

The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.

Mineralocorticoid receptor antagonists

The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.

Oxazole derivatives useful as inhibitors of FAAH

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and the pharmaceutical compositions which comprise compounds of the formula (I) are disclosed too. 

The present invention is directed to certain Inidazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

Imidazole derivatives useful as modulators of FAAH and as FAAH imaging agents

The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, LUTS, depression, and anxiety.

Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists

This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

Anti-hypercholesterolemic compounds

This invention provides cholesterol absorption inhibitors of Formula (I), and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events. 

The present invention is directed to certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

Hydroisoindoline tachykinin receptor antagonists

The present invention is directed to certain hydropyranopyrrolidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

Octahydropyrano[3,4-C]pyrrole tachykinin receptor antagonists

The present invention is directed to certain hydroisoindoline compounds of formula I which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety. 

Growing community of inventors

Westfield, NJ, United States of America

Robert J DeVita